GoGLP1 Editorial Team
Our editorial team is composed of health content professionals who specialize in GLP-1 receptor agonist therapy, metabolic medicine, clinical pharmacology, and telehealth platform evaluation. Together, we produce and review every article published on goglp1.com.
Our Approach
goglp1.com is an independent health information resource focused exclusively on GLP-1 receptor agonist medications, including semaglutide, tirzepatide, and emerging therapies. Our content is produced following a rigorous editorial policy that emphasizes evidence-based reporting, clinical accuracy, and transparency about our commercial relationships.
Every article undergoes multiple rounds of review before publication:
- Research and sourcing: All clinical claims are sourced from peer-reviewed medical literature, FDA guidance documents, and official prescribing information.
- Factual accuracy: Data points, pricing, and regulatory details are verified against primary sources and re-checked on a regular schedule.
- Editorial review: Content is reviewed for clarity, balance, and appropriate context — including potential risks and limitations of GLP-1 therapy.
- Commercial independence: Our editorial process is separate from our commercial relationships. Provider reviews and rankings are based on standardized evaluation criteria, not advertising agreements.
Areas of Expertise
The editorial team brings collective expertise across the following domains:
Clinical Pharmacology
In-depth knowledge of GLP-1 receptor agonist mechanisms, pharmacokinetics, drug interactions, and dosing protocols for both branded and compounded formulations.
Patient Education
Experience translating complex medical information into accessible, actionable guidance for patients considering or currently using GLP-1 therapy.
Telehealth Platform Evaluation
Standardized methodology for evaluating GLP-1 telehealth providers, including pricing transparency, prescribing practices, pharmacy partnerships, and customer support quality.
Regulatory Analysis
Tracking FDA approvals, compounding regulations (503A/503B), state-level prescribing requirements, and drug shortage implications for GLP-1 medications.
Insurance & Access Navigation
Practical guidance on insurance coverage, prior authorization, patient assistance programs, and cost-saving strategies for GLP-1 medications.
Nutrition & Lifestyle Support
Evidence-based dietary and lifestyle guidance for patients on GLP-1 therapy, including titration-phase nutrition, side effect management, and long-term maintenance strategies.
Content Standards
All content published on goglp1.com adheres to the following standards:
- Evidence-based: Every clinical claim cites peer-reviewed research, FDA documentation, or official prescribing information. We do not publish unsubstantiated health claims.
- Transparent: Our affiliate disclosures clearly identify commercial relationships. Provider reviews disclose any referral arrangements.
- Current: Medication pricing is re-verified on a regular schedule. Regulatory changes and new FDA actions are incorporated within 48 hours of publication.
- Balanced: We present both benefits and risks of GLP-1 therapy. We do not promote any specific medication or provider over others without disclosing the basis for comparison.
- Accessible: Content is written at a level appropriate for patients and consumers, not just healthcare professionals. Medical terminology is explained in plain language.
Corrections & Feedback
We take accuracy seriously. If you find an error in our content or have concerns about the accuracy of any article, please contact us through our contact page. We investigate all substantive accuracy concerns and publish corrections when warranted.
For more details about our editorial standards, review methodology, and sourcing practices, see our editorial policy.
Trust center
Review how we research, verify, and disclose content decisions across medical, editorial, and legal pages.